In brief: Spinraza recommended for funding on NHS

Spinraza has been recommended for funding on the NHS in the UK, Biogen has confirmed.

The positive recommendation from NICE is for the treatment of infants, children and adults with 5q spinal muscular atrophy (SMA), including pre-symptomatic and symptomatic SMA Types 1, 2 and 3.

SMA is a rare, debilitating and life-threatening disease that results in severe, progressive muscular atrophy and weakness.

“This is a momentous occasion for patients and their families and the result of a strong collaboration between Biogen, NICE, NHS and the SMA community,” said Chirfi Guindo, Executive Vice President, Global Product Strategy and Commercialisation at Biogen.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news